|

MindMed Financial Results & Business Update Q2 2021 ( Where Does MNMD/MMED Go From Here?)

ByPsychedelic Spotlight

MindMed’s Financial Results & Business Update for Q2 2021 are out!
In this episode, we’ll discuss MindMed, ( MMED: NEO), (MNMD: NASDAQ), (MMQ: FRA), who recently announced their Q2 financials and gave a business update.
This was an important, transitional quarter for the company for several reasons.

First, and perhaps most significantly, during Q2, co-founder JR Rahn stepped down as CEO, being replaced by Robert Barrow, who was previously Chief Development Officer.

Second, in terms of progress in the mission to heal mental health, MindMed made several strides in this quarter, which we’ll discuss today.

Pertinent links:

MindMed’s CEO Jr Rahn Steps Down:
https://thepsychedelicinvestor.com/2021/06/09/mindmed-announces-chief-executive-officer-transition/

Project Angie Update:
https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/

MindMed’s Collaboration with NextStage Therapeutics:
https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/

MindMed’s Pharmacogenetic Study:
https://thepsychedelicinvestor.com/2021/05/26/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to-help-guide-personalized-dosing/

MMED’s Q2 Financial Results & Business Update:
https://thepsychedelicinvestor.com/2021/08/13/mindmed-announces-2021-q2-financial-results-cash-balance-of-157-usd-million-195-cad-million-to-execute-on-diverse-clinical-pipeline/

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MindMedStock #MNMD

Similar Posts

  • Is Compass Pathways a GOOD INVESTMENT? (CMPS stock analysis)

    Listen, Videos

    In this episode, we take a deep dive into Compass Pathways (CMPS), a psychedelic-medicines company aiming to treat depression with psilocybin.

    To understand Compass Pathways (CMPS ), as a company and as an investment, you have to study 5 things:

    What problem is Compass Pathways trying to solve?
    CMPS’ clinical trial, treating depression with psilocybin
    The founders and leaders of Compass Pathways
    Compass’ Financials
    Is CMPS stock a good investment for a retail investor?

    As the psychedelic stocks sector takes off, Compass Pathways, alongside MindMed (MMED / MMEDF), looks poised to lead the pack. No other psychedelic-medicines company is as advanced in a clinical trial as is Compass Pathways (CMPS). CMPS has a phase 2b trial to test the effectiveness of psilocybin in treating Treatment-Resistant Depression could be game changing, and make for a great investment opportunity.
    Let me know in the comments what you guys think. Is Compass Pathways a GOOD INVESTMENT? Will the CMPS stock skyrocket in 2021?

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    Resources:
    https://compasspathways.com/

    https://www.webmd.com/depression/understanding-depression-basics#1

    https://www.psychiatry.org/patients-families/depression/what-is-depression

    https://www.nimh.nih.gov/health/statistics/major-depression.shtml

    https://www.webmd.com/depression/guide/depression-treatment-options#1

    https://www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=Inotherwordsantidepressantsare,foundtobeequallyeffective

    https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2222-4#:~:text=Treatmentresistantdepression(TRD),MDDpatientpopulation1

    https://www.beckleyfoundation.org/psilocybin-for-depression-2

    https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows

    https://compasspathways.com/our-research/psilocybin-therapy/about-psilocybin-therapy/#from-subnav

    https://psychedelicreview.com/person/ekaterina-malievskaia/

    https://compasspathways.com/team-member/george-goldsmith/
    https://compasspathways.com/team-member/lars-christian-wilde/

    https://www.reuters.com/article/us-compass-pathways-ipo/peter-thiel-backed-compass-pathways-files-for-u-s-ipo-idUSKBN25O31T

    https://www.globenewswire.com/news-release/2019/05/15/1825506/0/en/Anxiety-Disorder-and-Depression-Treatment-Market-To-Reach-USD-18-90-Billion-By-2026-Reports-And-Data.html

    https://www.treehugger.com/facts-about-magic-mushrooms-4868810
    https://psychedelicreview.com/person/ekaterina-malievskaia/

    #CompassPathways #CMPS #PsychedelicStocks #MindMed #MMED #MMEDF #PsychedelicStocks #ThePsychedelicInvestor

  • Removing Barriers of Accessibility to Psychedelics with Brett Waters

    Listen, Podcasts

    Brett also introduces the collaborative efforts of Reason for Hope’s team, which includes strategic minds from various fields, working together in drafting legislation, preparing legal briefings, educating legislators, and building advocacy coalitions. Currently, Reason for Hope focuses on establishing MDMA- and psilocybin-assisted therapy expanded access pilot programs for those unable to wait for FDA approval.

  • Industry NEWS: The GOOD, The BAD, And The UGLY / New Psychedelic Studies, Legalization Bills & MORE!

    Listen, Videos

    Hey guys! In this week’s general industry news, we’ll cover some interesting developments. Some are probably going to make some of our viewers turn away from this week’s episode as they discover some pretty “depressing” statistics about North America’s current mental state. However, for those who stick around, you might end up finding that there might be a light at the end of the tunnel as you discover that psilocybin’s benefits might be extended to treat certain

    Enjoy!
    Links:
    Psilocybin & Migraines: https://www.psypost.org/2021/05/a-single-dose-of-psilocybin-has-a-lasting-therapeutic-effect-on-migraine-headache-according-to-a-new-placebo-controlled-study-60793

    Increased depression in North America:
    https://www.meetfieldtrip.com/news/news-details/2021/Canadians-Are-Not-OK-83-of-Canadians-Report-One-Or-More-Symptoms-of-Depression-With-Many-Turning-To-Substances-To-Cope-With-Negative-Emotions-During-COVID-19-Pandemic-According-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx

    https://www.meetfieldtrip.com/news/news-details/2021/More-than-80-of-Americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-COVID-19-Pandemic-according-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx

    Opioid Overdose In Ontario:
    https://www.cp24.com/news/opioid-overdose-deaths-up-75-per-cent-in-ontario-during-covid-19-pandemic-new-report-1.5434080

    FDA Greenlights Ketamine:
    https://psychedelicspotlight.com/ketamine-study-parkinsons-disease-treatment/

    California Bill to Decriminalize Psychedelics Passes Senate Floor:
    https://www.marijuanamoment.net/california-bill-to-legalize-possession-of-psychedelics-heads-to-senate-floor-after-committee-action/

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @thepsychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video editing: @themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #PsychedelicIndustry

  • AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results)

    Learn, Videos

    AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results) Today, we’ll be sharing some GAME changing news for the entire psychedelic-medicines industry!

    First, we’ll start with some inspiring results from a few MDMA studies and their implications for companies such as Numinus (NUMI), MindMed (MMED / MNMD / MMQ) and Atai Life Sciences. First we’ll cover MAPS’ Phase III MDMA To Treat PTSD Trial Results. Then, we’ll focus on another study’s results, which implies that MDMA could be an effective treatment for alcoholism.

    Then, we’ll shift our focus towards an update on Texas, one of the more conservative U.S. states, and its approval of a Psychedelics Research Bill.

    Finally, we’ll share some of the oddest and most exciting news from this week: AI might potentially disrupt the psychedelic industry in the next few decades through the creation of psychedelic medicines.

    Timestamps:

    0:00 – Intro
    1:24 – Maps Phase III Trial Testing MDMA to treat PTSD RESULTS & Implications for
    Numinus (NUMI), MindMed (MMED / MNMD / MMQ ), Atai, etc.
    3:23 – Imperial College of London Study testing MDMA-assisted psychotherapy to treat Alcoholism
    7:29 – Texas House Approves a Psychedelic Research Bill
    9:34 – Scientists are Using AI to Develop New Psychedelic Drugs

    Links to Maps Phase III MDMA trial to treat PTSD : https://www.nytimes.com/2021/05/03/health/mdma-approval.html
    https://maps.org/news/media/9122-maps-phase-3-trial-of-mdma-assisted-therapy-for-ptsd-achieves-successful-results-for-patients-with-severe-chronic-ptsd

    Links to the Imperial College of London MDMA study to treat alcoholism: https://www.telegraph.co.uk/health-fitness/body/mdma-cured-alcoholism-inside-remarkable-ectsasy-trial-offering/
    https://www.telegraph.co.uk/news/2021/02/22/mdma-could-used-treat-alcohol-addiction/

    Link to the Texas House Psychedelics Research Bill: https://www.marijuanamoment.net/texas-house-approves-psychedelics-research-bill-as-marijuana-reform-measures-also-advance/

    Link to the article “Scientists are Using AI to Develop New Psychedelic Drugs: https://doubleblindmag.com/artificial-intelligence/

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #MNMD

  • The Psychedelic Sector has Reached “Escape Velocity” | An interview with Cybin’s CEO (CYBN)

    Listen, Videos

    In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast.

    In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health?

    The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression?

    Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect.

    Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects.

    It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year.

    James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity.

    In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now.

    Enjoy the episode!

    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy
    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Cybin #Psilocybin #Psychedelics